Trichomegaly and other external eye side effects associated with epidermal growth factor

Cutaneous and Ocular Toxicology

Volumn 31, Issue 3, 2012, Pages 195-197

  Fraunfelder, Frederick T ^a   Fraunfelder, Frederick W ^a  

^a CASEY EYE INSTITUTE   (United States)

Author keywords

Conjunctivitis; Dry eyes; Meibomitis; Toxicity; Trichomegaly

Indexed keywords

CETUXIMAB; ERLOTINIB; GEFITINIB; PANITUMUMAB;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CONJUNCTIVITIS; CORNEA EROSION; CORNEA ULCER; DRUG WITHDRAWAL; DRY EYE; ERYTHEMA; EYE DISEASE; EYELID EDEMA; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEIBOMIANITIS; OCULAR PRURITUS; PHOTOPHOBIA; REGISTER; SKIN DEFECT; TRICHIASIS; TRICHOMEGALY;

ADULT; AGED; AGED, 80 AND OVER; EPIDERMAL GROWTH FACTOR; EYE; FEMALE; HAIR DISEASES; HUMANS; MALE; MIDDLE AGED;

EID: 84865339862     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2011.636118     Document Type: Article

References (9)

1. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side efects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-670. (Pubitemid 44436627)
2. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007;23:65-66. (Pubitemid 46146906)
3. Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea 2007;26:858-860. (Pubitemid 47220560)
4. Saif MW, Gnanaraj J. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol 2010;29:62-66.
5. Jazayeri F, Malhotra R. A case of acquired trichomegaly following treatment with erlotinib. BMJ Case Rep 2009;doi:10.1136/bcr.01.2009.1473.
6. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994;10:93-102. (Pubitemid 24045719)
7. Wilson SE, He YG, Weng J, Zieske JD, Jester JV, Schultz GS. Efect of epidermal growth factor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility and diferentiation of human corneal epithelial cells. Exp Eye Res 1994;59:665-678.
8. Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular fndings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor geftinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond) 2005;19:729-738. (Pubitemid 41030567)
9. Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009;7 Suppl 1:S5-21; quiz S22.